The patent gave information about the pharmaceutical composition of PPAR agonist and Nrf2 activators along with the method for using them in combination in the treatment of arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease (IBD), and asthma. Here, PPARA is linked to Arthritis.